Clinical Trials Logo

Buprenorphine Dependence clinical trials

View clinical trials related to Buprenorphine Dependence.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06008990 Recruiting - Pregnancy Related Clinical Trials

Maternal Brain Imaging in Opioid Use Disorder

Start date: August 1, 2023
Phase:
Study type: Observational

This research study aims to learn more about opioid use disorder (OUD) during pregnancy and how outcomes for pregnant women and their newborns can be improved. During pregnancy, people with OUD are prescribed medication-assisted therapy (MAT). The investigators are interested to know how the medication is broken down by the body during pregnancy and how effective it is. The investigators also want to learn if this medication and OUD have any effect on the different parts of the brain when compared to mothers without OUD.

NCT ID: NCT03923374 Recruiting - Opioid-use Disorder Clinical Trials

Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes

Mother/BabyOUD
Start date: September 15, 2018
Phase:
Study type: Observational [Patient Registry]

The objective of this study is to better understand the comprehensive integration of both clinical and genetic factors that will help to identify mothers who could be at an increased risk of poor response to opioid substitution and infants at risk of significant neonatal abstinence syndrome (NAS).

NCT ID: NCT03549312 Recruiting - HIV/AIDS Clinical Trials

Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy

Start date: February 1, 2018
Phase: Phase 4
Study type: Interventional

The study hypothesis is to determine the feasibility of switching HIV-HCV co-infected patients receiving methadone or buprenorphine/naloxone as opioid substitution therapy with suppressed HIV RNA viral load on current antiretroviral therapy to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF, Genvoya™) followed by 12 weeks of HCV antiviral therapy with sofosbuvir/velpatasvir (SOF/VEL, Epclusa™), followed then by switch to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF, Biktarvy™) for an additional 48 weeks.